



12TH WORLD CONGRESS OF THE
WORLD FEDERATION OF
NUCLEAR MEDICINE AND BIOLOGY



Australasian
Association of
NUCLEAR MEDICINE
SPECIALISTS



WFNMB Post Congress Symposium

Prostate Cancer: PET and Theranostics

Cairns Convention Centre, Queensland, Australia
April 26-27, 2018

ESMIT
European School of Multimodality Imaging & Therapy

ANZUP
Cancer Trials Group Limited

THURSDAY 26th APRIL

Session 1	<i>Clinical Overview of Prostate Cancer and Functional Imaging Options</i>	
8.00-8.05	Welcome and overview	A/Prof Paul Roach <i>Sydney, Australia</i>
8.05-8.30	Prostate cancer in 2018: a clinical overview	A/Prof Declan Murphy <i>Melbourne, Australia</i>
8.30-8.55	Functional imaging with PET/CT: Choline and ¹⁸ F-Fluciclovine	Prof Hossein Jadvar <i>Los Angeles, USA</i>
8.55-9.20	⁶⁸ Ga PSMA: chemistry	Prof Clemens Decristoforo <i>Vienna, Austria</i>
9.20-9.45	Functional Imaging with ⁶⁸ Ga PSMA PET/CT	Prof Richard Baum <i>Bad Berka, Germany</i>
9.45-10.10	⁶⁸ Ga PSMA: interactive cases / pearls & pitfalls	Dr Geoff Schembri <i>Sydney, Australia</i>
10.10-10.40	<i>Morning tea</i>	
Session 2	<i>Primary Staging of Prostate Cancer</i>	
10.40-11.10	Surgeon's perspective: Imaging and treating primary prostate cancer	A/Prof Declan Murphy <i>Melbourne, Australia</i>
11.10-11.35	Conventional Imaging (CT, bone scan, MRI): role and limitations	Dr Francesco Ceci <i>Los Angeles, USA</i>
11.35-12.00	Functional imaging with ⁶⁸ Ga PSMA PET/CT: role and limitations	Dr Marcello Rodari <i>Milan Italy</i>
12.00-12.15	Trials and evidence: what we know, don't know but need to know	A/Prof Louise Emmett <i>Sydney, Australia</i>
12.15-12.45	Panel discussion, Q&A and challenging cases	A/Prof Declan Murphy & A/Prof Michael Hofman
12.45-13.30	<i>Lunch</i>	
Session 3	<i>Biochemical Recurrence / Failure (BF)</i>	
13.30-13.55	Radiation Oncologist's perspective: Imaging and treating BF	A/Prof George Hruby <i>Sydney, Australia</i>
13.55-14.20	Conventional Imaging of BF (CT, bone scan, MRI): role and limitations	Dr Francesco Ceci <i>Los Angeles, USA</i>
14.20-14.45	Functional imaging of BF with ⁶⁸ Ga PSMA PET/CT: role and limitations	Dr Marcello Rodari <i>Milan Italy</i>
14.45-15.00	Trials and evidence: what we know, don't know but need to know	A/Prof Louise Emmett <i>Sydney, Australia</i>
15.00-15.30	Panel discussion, Q&A and challenging cases	A/Prof Emmett, A/Prof Hruby and Prof Ian Davis
15.30-16.00	<i>Afternoon Tea</i>	
Session 4	<i>Recent developments: New Tracers and New Technologies</i>	
16.00-16.25	New and future tracers for diagnosing prostate cancer	Prof Clemens Decristoforo <i>Vienna, Austria</i>
16.25-16.50	PET/MRI: is it better than PET/CT?	Dr Francesco Ceci <i>Los Angeles, USA</i>
16.50-17.00	Panel discussion, Q&A, close	A/Prof Paul Roach <i>Sydney, Australia</i>

FRIDAY 27th APRIL

Session 5	<i>Systemic Therapy of Prostate Cancer</i>	
8.00-8.05	Welcome and overview	A/Prof Paul Roach <i>Sydney, Australia</i>
8.05-8.30	Treating prostate cancer: state of the art radiation oncology	A/Prof George Hruby <i>Sydney, Australia</i>
8.30-8.55	Treating prostate cancer: state of the art systemic therapy	Prof Ian Davis <i>Melbourne, Australia</i>
8.55-9.15	¹⁷⁷ Lu PSMA therapy: Overview, logistics, practicalities	Prof Clemens Decristoforo <i>Vienna, Austria</i>
9.15-9.40	¹⁷⁷ Lu PSMA therapy: local experience, indications, evidence base	A/Prof Michael Hofman <i>Melbourne, Australia</i>
9.40-10.05	<i>Morning tea</i>	
Session 6	<i>Systemic therapy of Prostate Cancer: New and Future Therapeutic Radionuclides</i>	
10.05-10.35	¹⁷⁷ Lu PSMA theranostics: local experience	Prof Richard Baum <i>Bad Berka, Germany</i>
10.35-11.05	Approach to dosimetry and new α and β therapies for prostate cancer	Dr Aviral Singh <i>Bad Berka, Germany</i>
11.05-11.30	²²³ Ra therapy (Xofigo)	Prof Homer Macapinlac <i>Houston USA</i>
11.30	Wrap-up and close	A/Prof Paul Roach <i>Sydney, Australia</i>